Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immersive

- PMLiVE

Ten years at the forefront of patient experience

This month marks ten years of Hive, which has prompted us to reflect on how the world has changed over the last decade, and how it is going to change...

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

- PMLiVE

World Cancer Day and the role of people-centred care

How people-centred is current cancer care? To support #WorldCancerDay, we explore this question, and look at the ways we can individually and collectively reduce the burden of cancer.

Porterhouse Medical Group

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Real patient voices

The #Human behind every number project

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

Patient engagement changes people’s lives…

Find out how one family’s experience of CF led to the development of a game which made essential physio a positive experience for everyone involved.

Cuttsy + Cuttsy

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

- PMLiVE

FDA’s year-end approvals take annual tally to 46

Rhopressa and Steglatro were among the final medicines licensed last year

1. Blood Test Results

Health literacy… it’s not just plain English

In this day and age, you would think that clear communication would be second nature to us all, but this is not so. In our digital world misunderstanding and confusion...

Cuttsy + Cuttsy

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links